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ABSTRACT
HIV-1 integrase (IN) is a validated target for developing antiret-
roviral inhibitors. Using affinity acetylation and mass spectro-
metric (MS) analysis, we previously identified a tetra-acetylated
inhibitor (2E)-3-[3,4-bis(acetoxy)phenyl]-2-propenoate-N-[(2E)-
3-[3,4-bis(acetyloxy)phenyl]-1-oxo-2-propenyl]-L-serine methyl
ester; compound 1] that selectively modified Lys173 at the IN
dimer interface. Here we extend our efforts to dissect the
mechanism of inhibition and structural features that are impor-
tant for the selective binding of compound 1. Using a subunit
exchange assay, we found that the inhibitor strongly modulates
dynamic interactions between IN subunits. Restricting such
interactions does not directly interfere with IN binding to DNA
substrates or cellular cofactor lens epithelium-derived growth
factor, but it compromises the formation of the fully functional
nucleoprotein complex. Studies comparing compound 1 with a
structurally related IN inhibitor, the tetra-acetylated-chicoric
acid derivative (2R,3R)-2,3-bis[[(2E)-3-[3,4-bis(acetyloxy)phe-
nyl]-1-oxo-2-propen-1-yl]oxy]-butanedioic acid (compound 2),
indicated striking mechanistic differences between these
agents. The structures of the two inhibitors differ only in their
central linker regions, with compounds 1 and 2 containing a
single methyl ester group and two carboxylic acids, respec-
tively. MS experiments highlighted the importance of these
structural differences for selective binding of compound 1 to
the IN dimer interface. Moreover, molecular modeling of com-
pound 1 complexed to IN identified a potential inhibitor binding
cavity and provided structural clues regarding a possible role of
the central methyl ester group in establishing an extensive
hydrogen bonding network with both interacting subunits. The
proposed mechanism of action and binding site for the small-
molecule inhibitor identified in the present study provide an
attractive venue for developing allosteric inhibitors of HIV-1 IN.
Recent development of the first clinically useful strand-
transfer inhibitor (STI) Raltegravir (MK-0518) has validated
HIV-1 integrase (IN) as a important antiretroviral target
(Summa et al., 2008). The enzyme functions as a multimer to
insert the reverse-transcribed RNA genome into the host
chromosome through two reaction steps. In the first step,
termed 3-processing, IN cleaves a GT dinucleotide from each
end of the viral DNA. In the second step, termed strand
transfer, IN catalyzes concerted integration of the processed
viral DNA ends into chromosomal DNA. Studies with puri-
fied recombinant protein and model DNA substrates indi-
cated that the individual protein monomers establish com-
plementary contacts with DNA substrates with the subunit-
subunit contacts playing a crucial role in the formation of the
functional nucleoprotein complexes (Engelman et al., 1993;
van Gent et al., 1993; van den Ent et al., 1999; Zhao et al.,
2008). Although a dimeric protein is sufficient to process each
3-end, a tetramer is needed to carry out the concerted inte-
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gration of both viral ends (Faure et al., 2005; Guiot et al.,
2006; Li et al., 2006).
After the discovery of the transcriptional coactivator lens
epithelium-derived growth factor (LEDGF) as a key cellular
cofactor for HIV-1 integration, LEDGF-IN interactions have
become a new venue for antiviral drug design (De Rijck et al.,
2006; Al-Mawsawi et al., 2008; Hou et al., 2008; Busschots et
al., 2009). LEDGF directly interacts with IN through a C-
terminal region termed the integrase binding domain (IBD)
(Cherepanov et al., 2004; Vanegas et al., 2005) and tethers
the preintegration complex to chromatin (Maertens et al.,
2003; Emiliani et al., 2005; Llano et al., 2006b; Shun et al.,
2007). Overexpression of the IBD, which tightly binds IN but
lacks an N-terminal nuclear localization signal or the chro-
matin binding domain of LEDGF, severely inhibits HIV-1
replication in cell culture assays (De Rijck et al., 2006).
Furthermore, HIV-1 strains resistant to the STI were fully
susceptible to inhibition by the IBD (De Rijck et al., 2006). It
is intriguing that the IBD is significantly more effective at
suppressing HIV-1 replication in LEDGF-deficient cells (555-
fold) compared with cells containing LEDGF at normal levels
(30-fold) (Llano et al., 2006a). These observations suggest
that in the absence of competing LEDGF levels, the IBD
could effectively engage IN and adversely affect its function.
We recently observed that the high exchange rate among
IN subunits in multimers can be reduced by IBD binding
(McKee et al., 2008). The preformed IN-IBD complex is ca-
pable of binding donor DNA but fails to catalyze concerted
integration (McKee et al., 2008). These findings suggested
that the dynamic interplay between IN subunits is essential
for the assembly of the fully functional nucleoprotein com-
plex and that restricting the molecular movement of individ-
ual subunits within a multimer could compromise catalytic
processes. Consistent with this, IBD-derived peptides have
been shown to stabilize a multimeric form of IN and impair
HIV-1 infection (Hayouka et al., 2007; Al-Mawsawi et al.,
2008).
Although studies with the IBD have provided proof-of-
concept for targeting the dynamic structure of free IN, a focus of
developmental efforts is to discover small-molecule inhibitors
that can modulate the subunit-subunit interactions. In this
regard, small-molecule inhibitors that have been shown previ-
ously to selectively bind at the IN dimer interface are worth
revisiting. For example, 3,4-dihydroxyphenyltriphenylarso-
nium bromide and a coumarin-based inhibitor have been re-
ported to bind IN at sites that partly overlap the IBD binding
pocket (Molteni et al., 2001; Al-Mawsawi et al., 2006). Using
affinity acetylation andMS analysis, we previouslymapped one
contact between the small-molecule inhibitor (2E)-3-[3,4-
bis(acetoxy)phenyl]-2-propenoate-N-[(2E)-3-[3,4-bis(acetyloxy)-
phenyl]-1-oxo-2-propenyl]-L-serine methylester (compound 1;
Fig. 1) and Lys173 located at the IN dimer interface (Shkriabai
et al., 2004). However, the mechanisms of action of this and
similar compounds have not been elucidated.
In the present study, we extend our previous research with
compound 1. Using a subunit exchange assay, we have ob-
served that the inhibitor modulates dynamic interactions
between IN subunits in a dose-dependent fashion. Further-
more, we have found that the central linker region of 1 is
essential for selective binding of the inhibitor to the IN dimer
interface. Moreover, molecular modeling experiments have
enabled us to propose contact amino acids and define a po-
tential small-molecule binding cavity within HIV-1 IN, which
may represent a new therapeutic target.
Materials and Methods
Preparation of Wild-Type and Mutant Recombinant HIV-1
IN. Full-length wild-type and soluble (F185K/C280S) integrase pro-
teins were expressed in Escherichia coli. The point mutations were
introduced in the wild-type IN sequence using a polymerase chain
reaction mutagenesis kit (QIAGEN, Valencia, CA). Wild-type and
mutant IN proteins were purified according to procedures described
previously (McKee et al., 2008).
Assay for HIV-1 IN Inhibitors. Compounds 1 and 2 were pre-
pared as reported previously (Lin et al., 1999). MALDI-ToF analysis
confirmed successful synthesis and a high degree of purity of the
full-length products (Supplemental Fig. 1). The preparations of com-
pound 1 and 2 were dissolved in dimethyl sulfoxide to make 10 mM
stock solutions and were stored at 20°C until use. The compounds
were highly stable throughout the course of our studies.
Measurement of in vitro IC50 values was carried out as described
previously (Hazuda et al., 1994). In brief, a short double-stranded
DNA (a hybrid of the 21- and 19-oligomer synthetic oligonucleotides)
representing the preprocessed HIV-1 U5 LTR end was immobilized
on a CovaLink microtiter plate (NUNC/Thermo Fisher Scientific,
Rochester, NY) via carbodiimide-mediated condensation. After incu-
bation with IN, a biotinylated target oligonucleotide was added, and
the strand transfer reaction was allowed to proceed. The plates were
washed thoroughly and blocked before incubation with alkaline
phosphatase-conjugated streptavidin (Pierce, Rockford, IL). After
additional washing, para-nitrophenylphosphate was added, and the
development of p-nitrophenolate was determined spectrophotometri-
cally at 405 nm.
Mass Spectrometric Analyses. The acetylation reactions for
short control peptides and recombinant IN have been described
Fig. 1. A, structures of compounds 1 and 2. B, the inhibition profiles of
recombinant wild-type IN with compounds 1 (Œ) and 2 (E). The mean
values for at least three experiments are presented. The deviation for
each measurement was 10%.
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previously (Shkriabai et al., 2004). In brief, 5 M peptides were
incubated with 500 M compound 1 or 2 for 30 min at 37°C, and the
reaction products were analyzed with MALDI-ToF using an Axima
CFR instrument (Shimadzu Biotech, Manchester, UK) and the
-cyano-4-hydroxy-cinnamic acid matrix. To identify the sites in
HIV-1 IN modified by 1 and 2, the protein was first incubated with
increasing concentrations of inhibitors and then digested by trypsin,
and the proteolytic fragments were analyzed with Shimadzu
MALDI-ToF and Waters quadrupole/time of flight-II instruments
(Manchester, UK) as described previously (Shkriabai et al., 2004).
DNA-IN Interactions. Disulfide-mediated IN-DNA cross-linking
has been described previously (Zhao et al., 2008). The assays used
IN(E152C) protein and a 21-oligomer specific DNA with a cross-
linkable analog at the G2 position (Zhao et al., 2008 provides detailed
preparation of the protein and DNA). The cross-linking reactions
were performed by incubating 1 M IN with equimolar DNA duplex
in 50 mM HEPES, pH 7.0, 100 mM NaCl, 5 mM MgCl2, and 10%
glycerol at 37°C for 20 min. The reactions were quenched by the
addition of 20 mM methyl methanethiosulfonate and subjected to
SDS-PAGE analysis. Free protein and protein-DNA complexes were
visualized by Western blots using IN antiserum.
Assay for IN Subunit Exchange. A subunit exchange assay was
performed as described previously (McKee et al., 2008). In brief,
histidine-tagged IN (50 nM) was preincubated in pull-down (PD)
buffer [50 mM HEPES, pH 7.1, 300 mM NaCl, 100 mM imidazole, 2
mM MgCl2, 2 mM -mercaptoethanol, and 0.1% (v/v) Nonidet P-40]
for 30 min at room temperature with and without increasing
amounts of ligands (1 or 2). An equimolar amount of tag-free IN (50
nM) was then added, and subunit exchange was allowed for 60 min
at room temperature. Samples were briefly centrifuged for 2 min at
1000g to remove nonspecific aggregates. Supernatants were incu-
bated with nickel-agarose beads (GE Healthcare, Chalfont St. Giles,
Buckinghamshire, UK) for 30 min in the presence of bovine serum
albumin (0.1 mg/ml). After the affinity pull-down of protein-protein
complexes, the resin was washed three times with the PD buffer and
boiled in SDS-PAGE loading buffer. Histidine-tagged and tag-free
INs were then separated by SDS-PAGE and visualized by Western
blots using a mouse monoclonal IN antibody (from the AIDS Re-
search and Reference Reagent Program, National Institutes of
Health, Bethesda, MD).
IN Cross-Linking Assay. The IN cross-linking assay was per-
formed as described previously (Li et al., 2006). In brief, IN (100 nM)
was preincubated in buffer [50 mM HEPES, pH 7.1, 300 mM NaCl,
2 mM MgCl2, 1 mM dithiothreitol, and 0.1% (v/v) Nonidet P-40] for
30 min at room temperature with or without compound 1. The
bifunctional reagent BS3 (Pierce) was then added at 100 M final
concentration, and the mixture was incubated for 15 min at room
temperature. Reactions were quenched by the addition of Tris/
NaOAc and boiled in the SDS-PAGE loading buffer. INs were sepa-
rated by SDS-PAGE and visualized by Western blot using a mouse
monoclonal IN antibody [HIV-1 INMonoclonal Antibody (2C11) from
Dr. Dag E. Helland obtained through the AIDS Research and Refer-
ence Reagent Program, Division of AIDS, National Institute of Al-
lergy and Infectious Diseases, National Institutes of Health].
Protein Solubility Test. IN (100 nM) was preincubated in PD
buffer [50 mM HEPES, pH 7.1, 300 mM NaCl, 100 mM imidazole, 2
mMMgCl2, 2 mM -mercaptoethanol, 0.1% (v/v) Nonidet P-40] for 60
min at room temperature with or without 250 M ligand (compound
1 or 2). Samples were then centrifuged for 10 min at 5000g. Pellets
and supernatants were analyzed by SDS-PAGE and detected by
Western blot as described above.
Monitoring the Effects of Compounds on IN-LEDGF Inter-
actions. LEDGF-IN binding assays were performed as described
previously (McKee et al., 2008). In brief, histidine-tagged IN (100
nM) was preincubated in PD buffer for 30 min at room temperature
with and without increasing amounts of ligands (compounds 1 or 2).
Tag-free LEDGF (300 nM) was then added and incubated for 60 min
at room temperature. Samples were centrifuged and pulled down by
a nickel-agarose resin as described above. The bound proteins were
subjected to SDS-PAGE separation, and LEDGF was visualized by
Western blot using a mouse monoclonal LEDGF antibody (BD Bio-
sciences, San Jose, CA).
LEDGF Binding to Wild-Type and Mutant IN. LEDGF (1 M)
was incubated with 600 nM histidine-tagged IN (wild type or mu-
tant) in binding buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
2 mM MgCl2, 35 mM imidazole, 2 mM -mercaptoethanol, and 0.1%
(v/v) Nonidet P-40] for 60 min at room temperature. Samples were
pulled down by a nickel-affinity resin for 30 min in the presence of
bovine serum albumin (0.1 mg/ml). The resin was washed three
times with the same buffer, and the bound proteins were subjected to
SDS-PAGE separation and visualized by Coomassie blue staining.
Size-Exclusion Chromatography. Protein solutions (10 M) in
storage buffer (50 mM HEPES, pH 7.4, 1 M NaCl, 7.5 mM CHAPS,
10 mM dithiothreitol, and 10% glycerol) were subjected to size-
exclusion chromatography using a Superdex 200 10/300 GL column
(GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) and run-
ning buffer (50 mM HEPES, pH 7.4, 1 M NaCl, and 10% glycerol).
The column was calibrated with the following proteins: conalbumin
(75 kDa), carbonic anhydrase (29 kDa), ribonuclease A (13.7 kDa),
and aprotinin (6.5 kDa). Proteins were detected by absorbance at
280 nm.
Molecular Docking Studies. All simulations were performed on
a Silicon Graphics O2 workstation (SGI, Mountain View, CA). The
coordinates of the catalytic core domain (CCD) of IN were extracted
from the crystal structure 2B4J (Cherepanov et al., 2005) obtained
from the Research Collaboratory for Structural Bioinformatics Pro-
tein Data Bank (available at http://www.rcsb.org/pdb/home/
home.do). The initial three-dimensional model of compound 1 was
generated using the biopolymer module within the Insight II soft-
ware package (Accelrys Inc., San Diego, CA). Molecular docking
studies were performed using the Autodock program (version 3.0),
which allows virtual docking of a fully flexible ligand within a rigid
defined binding pocket (Goodsell and Olson, 1990). A “target grid”
covering both putative binding cavities (including Lys173, His171,
Asp167, Trp131, and Thr125 residues) was generated. Polar hydro-
gens were added, Kollman charges were assigned, and three-dimen-
sional affinity grid maps were calculated for each atom type [C, A
(aromatic C), N, O, S, and H] using the Autogrid module. For the
ligand, hydrogens were added, Gasteiger charges were assigned, and
the rotatable bonds were determined by the AutoTors module. The
docking parameters were as follows: genetic algorithm, trials of 50
dockings, random starting position and conformation, rotation step
ranges of 5°, and 1 million energy evaluations. The Autodock pose
showing the lowest binding energy was extensively energy-mini-
mized using the Discover module of Insight II software using the
CFF91 force field and the steepest descent method. Both protein and
ligand were left flexible, and no constraints were applied.
Results
Compounds 1 and 2 (Fig. 1A) have been synthesized
previously (Lin et al., 1999) as structural analogs of chico-
ric acid (CA) (Supplemental Fig. 2). Compound 2 repre-
sents tetra-acetylated CA. Compound 1 also contains di-O-
tetra-acetyloxycinnamoyl groups, but it differs significantly
from 2 and CA in the central linker region. For example, 1
possesses a noncharged methyl ester group, whereas 2 and
CA contain two polar carboxylic acids (Fig. 1). Despite these
structural differences, the compounds inhibited IN with sim-
ilar IC50 values (Lin et al., 1999) (Fig. 1B), and they were
assumed to exhibit similar mechanisms of action. However,
more recent studies have suggested that 1 may differ from
authentic CA compounds in its interactions with IN. For
example, using affinity acetylation coupled withMS analysis,
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we have demonstrated that 1 selectively acetylates Lys173
located at the protein dimer interface (Shkriabai et al., 2004)
(Fig. 2). In contrast, CA has been reported to interact at the
IN active site (Healy et al., 2009), which is significantly
distanced from the dimer interface.
To clarify these differences, we compared compounds 1 and
2 for their interactions with HIV-1 IN. We chose compound 2
as a representative CA for the following reasons. The de-
tailed in vitro IN activity and cell culture infectivity assays
indicated that 2 and hydroxylated CA exhibit the same mech-
anism of action (Lin et al., 1999; Pluymers et al., 2000).
Furthermore, in common with 1, compound 2 contains di-O-
acetyl groups that would enable us to compare interactions of
the two compounds with IN using the affinity acetylation and
MS analysis approach (Shkriabai et al., 2004).
Using model peptides, we have demonstrated previously
that aryl di-O-acetyl compounds could effectively acetylate
lysine, cysteine, and tyrosine side chains (Shkriabai et al.,
2004). Therefore, to compare acetylation reactions for 1 and
2, we used a short control peptide (HDMNKVLDL) contain-
ing a single lysine residue. As expected, no acetylation was
detected at low compound concentrations (5 M) because of
the lack of specific interactions. In contrast, 500 M 1 and 2
effectively acetylated the target lysine residue (data not
shown). Comparison of the modified peak intensities indi-
cated that aryl di-O-acetyl groups in the tested compounds
exhibit very similar chemical reactivities.
In contrast, a striking difference was observed between
compounds 1 and 2 in their interactions with HIV-1 IN (Fig.
2). Compound 1 at concentrations similar to its IC50 value
effectively acetylated Lys173, whereas compound 2 failed to
modify this residue even at very high concentrations (200 M)
(Fig. 2). No specific acetylation of IN was detected with low
micromolar concentrations of 2, suggesting that in the protein-
inhibitor complex, di-O-acetyl groups were not positioned close
enough to react with the side chains of lysine, cysteine, or
tyrosine residues. At elevated concentrations (200 M) of 2,
multiple lysine residues were acetylated. This could be due to
nonspecific modes of modifying surface residues. To test this
hypothesis, we performed control experiments using 500 M
concentration of primary amine modifying reagent sulfo-N-
hydroxysuccinimide-biotin. The modification profiles ob-
tained with 2 and sulfo-N-hydroxysuccinimide-biotin were
very similar, indicating that the affected residues were in-
deed targeted for their surface exposure rather than for spe-
cific interactions. Thus, our experiments did not reveal the
specific binding site for 2 but indicated marked differences in
1 and 2 binding to IN.
Further evidence for different mechanisms of actions for 1
and 2 emerged from IN-DNA binding studies. The results in
Fig. 3 show that 2 interfered with IN-DNA complex forma-
tion in a dose-dependent manner. These results are consis-
tent with a recently proposed molecular model (Healy et al.,
2009), in which the CA binding site partly overlaps with the
presumed donor DNA binding cleft. In contrast, 1 did not
directly interfere with IN-DNA interactions, suggesting an
alternative mechanism of action for this compound.
Fig. 2. Segments of quadrupole/time of flight mass spectra demonstrat-
ing selective acetylation of Lys173 with 1. A, IN  6.25 M 1; B, IN  25
M 1; C, IN 10 M 2; D, IN 200 M 2; E, free IN. The tryptic peptide
of IN containing acetylated Lys173 is indicated. C1 is unmodified tryptic
peptide (AMASDFNLPPVVAK) of IN, which serves as an internal
control.
Fig. 3. Effects of 1 and 2 on IN-DNA cross-linking. IN(E152C) was first
incubated with increasing concentrations of 1 (A) and 2 (B) and then
cross-linked to a specific DNA containing a cross-linkable analog at the
G2 position (G2). The reaction products were resolved by SDS-PAGE. The
bands corresponding to free IN and IN-DNA complex are indicated. A,
lane 1 molecular mass markers; lane 2, IN-DNA cross-linking in the
absence of 1. Lanes 3 to 10 contained increasing concentrations of 1 (1, 2,
4, 8, 16, 32, 64, and 128 M). B, lane 1, molecular mass markers; lane 2,
IN-DNA cross-linking in the absence of 2; lanes 3 to 9 contained increas-
ing concentrations of 2 (2, 4, 8, 16, 32, 64, and 128 M).
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Further experiments were performed to elucidate a mech-
anism of action for 1 (Figs. 4 and 5) and define the inhibitor
binding site in more detail (Figs. 6 and 7). Given that 1
selectively interacts with Lys173 located at the protein dimer
interface (Fig. 2), we examined whether 1 could affect the
dynamic interactions between IN subunits. For this purpose,
we used the subunit exchange assay devised by our group
(McKee et al., 2008) (Fig. 4A). This method monitors kinetic
interactions between the two wild-type proteins: histidine-
tagged IN (indicated as IN2 in the monomeric state and
IN2–IN2 in the dimeric state), and tag-free IN (indicated as
IN1 in the monomeric state and IN1–IN1 in the dimeric
state). Because of the effective exchange between individual
protein subunits, the tag-free protein within the IN1-IN2
complex can be quantitatively pulled down by a nickel-
affinity resin. To reveal whether the compounds can mod-
ulate these interactions, IN2-IN2 was first preincubated
with increasing concentrations of 1 or 2 and then exposed
to IN1-IN1. The data in Fig. 4B (lanes 5–10) show that 1
impaired dynamic exchange between IN subunits in dose-
dependent manner. In contrast, 2 tested at high concen-
trations had no detectable effect on IN subunit-subunit
exchange (Fig. 4B, lanes 11 and 12).
Dynamic modulation of subunit-subunit exchange can be
achieved either through 1 stabilizing the interacting IN
monomers into a multimeric state or by preventing multimer
formation through interference with subunit-subunit assem-
bly. To differentiate between these possibilities, order-of-
addition experiments were performed (Fig. 4C). Preincuba-
tion of 1 with IN2-IN2 and subsequent addition of IN1-IN1 to
the reaction mixture effectively interfered with the subunit-
subunit exchange (Fig. 4C, lane 2). However, 1 did not sig-
nificantly affect the preassembled IN1–IN2 complex (Fig. 4C,
lane 4). These findings suggest that 1 does not dissociate IN
multimers. Instead, 1 binds to multimeric IN and restricts
the ability of interacting subunits to exchange freely among
multimers.
Fig. 4. Effects of 1 and 2 on IN subunit-subunit interactions. Experimen-
tal design (A) and results (B). A, the subunit exchange between IN
multimers was tested by mixing the two wild-type IN proteins: IN1-IN1,
a tag-free form, and IN2-IN2, containing the histidine tag at its C termi-
nus. The full-length proteins are depicted as dimers (IN1–IN1) and (IN2–
IN2). Upon subunit-subunit exchange, three IN populations can be
formed: IN1–IN1, IN1–IN2, and IN2–IN2. Of these, IN2–IN2 and IN1–
IN2 can be pulled down by nickel-affinity resin through binding with the
histidine tag, whereas the tag-free IN1–IN1 is washed out. B, the IN1 and
IN2 proteins from the bound complexes were subjected to SDS-PAGE and
detected by Western blot. Lane 1, IN2 load; lane 2, IN1 load; lane 3, no
ligand or IN1 (non specific pull-down control); lane 4, the subunit-subunit
exchange in the absence of compounds; lanes 5 to 10, the subunit ex-
change reactions in the presence of increasing 1 concentrations (8, 16, 32,
64, 128, and 256 M); lanes 11 and 12, reactions in the presence of 128
and 256 M 2. C, order-of-addition experiments. Lanes 1 and 3, subunit
exchange reactions in the absence of compounds; lane 2, IN2-IN2 was
first preincubated with 1 and then exposed to IN1-IN1; lane 4, IN2-IN2
and IN1-IN1 were first mixed to carry out subunit exchange, and then 1
was added to the mixture.
Fig. 5. Effects of 1 on IN multimerization (A), solubility (B), and
LEDGF-IN binding (C). A, in parallel reactions, free IN (lane 1) and the
IN-1 complex (lane 2) were subjected to cross-linking with BS3, and the
reaction products were separated by SDS-PAGE. Migrations of molecular
mass markers and IN bands are indicated. B, lane 1, molecular mass
markers; lane 2, total (T) sample before centrifugation; lanes 3 and 4,
supernatant (S) and precipitate (P) fractions formed after centrifugation
of IN in the presence of 10% dimethyl sulfoxide; lanes 5 and 6, IN
solubility in the presence of 256 M 1. C, lane 1, LEDGF input; lane 2, no
ligand or IN (nonspecific pull down control); lane 3, LEDGF and IN
interactions in the absence of 1; lanes 4 to 8, assays with increasing 1
concentrations (8, 16, 32, 64, and 128 M).
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The effects of 1 on IN multimerization were also tested
using bifunctional cross-linkers and SDS-PAGE separation
(Fig. 5A). This approach has been instrumental in probing
IN structures in the synaptic complex and infected cells
(Cherepanov et al., 2003; Li et al., 2006). As expected (Li et
al., 2006), different multimeric species were observed with
the free protein. Upon the addition of 1, the intensity of the
monomeric band was significantly reduced. Similar quanti-
ties of dimeric IN bands were observed in free IN and the
IN-1 complex samples. Whereas a band corresponding to a
tetramer was enhanced at least by 50% in the protein-inhib-
itor complex compared with free IN. The observed cross-
linking patterns (Fig. 5A) were highly reproducible. Because
in the 1-IN complex, a monomer band was reduced and
multiple oligomeric species were detected, it is logical to
suggest that the inhibitor promotes protein multimerization
in general rather than stabilizes one particular multimeric
form of IN. For example, 1 could affect conformations of
interacting subunits so that the 1-IN complex is less flexible
(Fig. 4) and more susceptible to multimerization (Fig. 5A)
than free IN.
Next, we examined whether 1-induced protein multimer-
ization could affect IN solubility. Figure 5B shows that under
our assay conditions, free IN remained in solution and that 1
did not alter IN solubility. Given that LEDGF binds at IN
dimer interface adjacent to Lys173, we checked whether 1
could affect the IN-LEDGF complex formation. The results in
Fig. 5C indicate that 1 did not significantly affect protein-
protein interactions indicating that the primary binding sites
of 1 and LEDGF differ.
The following efforts were devoted to a more detailed char-
acterization of the sites of 1 binding to IN. Specific acetyla-
tion of Lys173 provided an important clue regarding one of
the contacts between the terminal di-O-acetyl group of the
inhibitor and the protein. However, comparative SAR studies
of 1 and 2 revealed an essential role of the central linker
region for determining binding and mechanistic properties of
these inhibitors. Indeed, 1 containing the methyl ester group
within the linker interacted with the IN dimer and modu-
lated dynamic interactions between the subunits (Figs. 2 and
4), but it did not directly affect IN-DNA interactions (Fig. 3).
In contrast, 2 possessing two central carboxylic acid groups
failed to bind to the IN dimer interface (Fig. 2) or modulate
subunit-subunit interactions (Fig. 4). Instead, 2 interfered
with the IN-DNA complex formation (Fig. 3).
To identify additional contact amino acids contributing to
specific binding of 1 to the protein dimer interface, we used
Fig. 6. Molecular docking studies for 1. A and B, two potential binding
pockets (colored in magenta and orange) at the CCD dimer interface.
These distinct sites are located immediately adjacent to one another. A
and B, two different views of the CCD dimer to better visualize individual
binding pockets. Individual subunits of IN are colored green and yellow.
The location of Lys173 and height (H), depth (D), and width (W) for each
cavity is indicated. C, the space-filling model for the CCD dimer-1 com-
plex showing that the inhibitor simultaneously interacts with both IN
monomers (green and yellow). The central methyl ester group is deeply
buried in the cavity and cannot be seen in this picture. Integrase active
site residues (Asp64, Asp116, and Glu152) on each monomer are shown in
red. D, key interactions with IN residues established by the central
methyl ester group and the linker region. The amino acids from green or
yellow subunits are colored accordingly.
Fig. 7. Biochemical analysis of IN mutants. A, size-exclusion chromatog-
raphy of wild-type and mutant proteins. Peaks corresponding to tetramer
(Tet) IN with estimated molecular masses of 111 kDa and a dimeric
(Dim) protein with estimate molecular masses of 54 kDa, are indicated.
B, effects of amino acid substitutions on recombinant IN activities. Top
image depicts strand transfer activities. Positions of 21-oligomer sub-
strate (21-S) and reaction products (STP) are indicated. Bottom image
displays 3-processing activities. The positions of 21-S and specific 19-
oligomer products (19-P) are shown. B, LEDGF binding to wild-type and
mutant INs: lane 1, molecular mass markers; lane 2, LEDGF input; lane
3, assay without IN (nonspecific pull-down control); lane 4, assay with
wild-type IN; lane 5, assay with E87A mutant; lane 6, assay with E96A
mutant; lane 7, assay with Y99A mutant; lane 8, assay with K103A
mutant.
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molecular modeling. Although full-length IN has not been
amenable to high-resolution structural studies, atomic struc-
tures of individual protein domains are available. Lys173 is
located in the CCD. Crystallographic studies indicated a
dimeric organization of this domain (Dyda et al., 1994). The
CCD contains the DDE motif coordinating the catalytic diva-
lent metals and an IBD binding site (Fig. 6). Analysis of the
protein surface surrounding Lys173 revealed two adjacent
pockets depicted in orange and magenta (Fig. 6, A and B).
The pocket in orange has been shown to tightly interact with
the LEDGF (Cherepanov et al., 2005; Hare et al., 2009).
Furthermore, the two small-molecule inhibitors (3,4-dihy-
droxyphenyltriphenylarsonium bromide and a coumarin-
based compound) have also been demonstrated to target this
site (Molteni et al., 2001; Al-Mawsawi et al., 2006). In con-
trast, the similarly sized cavity depicted in magenta has not
been implicated previously in small-molecule binding. It is
noteworthy that Lys173 is located at the boundary separat-
ing these distinct pockets (Fig. 6 A and B). Therefore, 1 could
potentially target either of the two similarly sized cavities.
To delineate between interactions at the two possible bind-
ing sites (magenta and orange), docking simulations were
performed using the Autodock software and a “target grid”
covering both putative binding cavities on the dimeric CCD
structure (see virtual docking details under Materials and
Methods). Table 1 shows the results for the 10 lowest binding
energy, which indicate a striking preference for 1 binding to
the site represented by “magenta” cavity (Fig. 6). The lowest
docking pose (5.30 kcal/mol) was further minimized using
Insight II software (see Materials and Methods).
The resulting molecular model for the CCD dimer-1 com-
plex is shown in Fig. 6, C and D. The inhibitor interacts with
both IN monomers. One di-O-acetyl group of 1 is located at
3.8 Å within Lys173 (subunit yellow), a distance compatible
with the specific acetylation of this position observed in the
MS experiments (Fig. 2). The central methyl ester group of
the inhibitor is buried deeply within the cavity where it binds
to IN through tight electrostatic and hydrophobic interac-
tions (Fig. 6, C and D). IN amino acids engaging the central
linker region include side chains of Glu87, Glu96, Tyr99, and
Lys103. These interactions could explain the importance of
the linker region for the selective binding of 1 to the IN
dimer.
To examine significance of these residues for IN function and
1 binding, we prepared purified recombinant proteins contain-
ing the following point substitutions: E87A, E96A, Y99A, and
K103A in the wild-type IN sequence. Size-exclusion chromatog-
raphy results in Fig. 7A show that these mutations affected IN
multimerization. For example, a peak corresponding to a tet-
rameric protein was reduced in all mutant proteins compared
with wild-type IN. We also examined acetylation of the mutant
proteins with 1. In sharp contrast with wild-type IN, Lys173
was not acetylated in any of the four mutant proteins, even in
the presence of elevated concentrations (200 M) of 1 (data not
shown). These experiments, however, did not fully delineate
whether Glu87, Glu96, Tyr99, and Lys103 directly or indirectly
contribute to 1 binding to IN as their substitutions affected IN
multimerization. Nevertheless, our findings highlight the im-
portance of a correctly assembled IN multimer for selective
binding of 1. Figure 7B shows that all of the mutant proteins
were catalytically inactive. Furthermore, E87A failed to bind
LEDGF, and the E96A, Y99A, and K103A substitutions re-
duced IN affinity for the cellular cofactor (Fig. 7C). Taken to-
gether, the mutagenesis studies highlighted the architectural
importance of this newly identified small-molecule binding cav-
ity for IN function and provide proof-of-concept for targeting
this site with allosteric inhibitors.
Discussion
Here we show for the first time that a small-molecule
compound inhibits HIV-1 IN catalytic function through allo-
steric modulation of dynamic interactions between the indi-
vidual protein subunits (Fig. 4). The highly dynamic nature
of free IN subunits is essential for the productive assembly of
the fully functional IN-vDNA complex (McKee et al., 2008).
Binding of 1 to free IN stabilizes the interacting subunits
(Fig. 4) and promotes protein multimerization (Fig. 5A). The
preformed protein-protein complex is capable of binding DNA
substrates (Fig. 3) because 1 does not seem to directly mask
the substrate binding channel in the retroviral enzyme (Figs.
2 and 6). Instead, 1 could compromise IN catalytic activities
by the following allosteric mechanisms. The restricted flexi-
bility of the preformed 1-IN complex may impede correct
positioning of the catalytic site on the cognate DNA sub-
strate. Alternatively, 1 could limit a conformational flexibil-
ity of IN, which is needed for the formation of the fully
functional nucleoprotein complex (Zhao et al., 2008).
Proposed mechanisms of action for 1 are reminiscent of
modulation of IN structure and function by LEDGF and its
IBD. For example, in vitro experiments have indicated that
the cellular cofactor effectively impairs IN subunit-subunit
exchange and promotes IN tetramerization (McKee et al.,
2008). The preassembled protein-protein complexes are ca-
pable of binding donor DNA but are defective for the con-
certed integration (Pandey et al., 2007; Raghavendra and
Engelman, 2007; McKee et al., 2008). These findings have
suggested that IN tetramers formed in IN-LEDGF and IN-
vDNA complexes are not identical. In contrast, the full-
length cofactor stimulates the catalytic reactions when IN-
vDNA complexes are preformed and then LEDGF is provided
(Pandey et al., 2007; Raghavendra and Engelman, 2007;
Hare et al., 2009). These in vitro observations, highlighting
the importance of the order of vDNA and LEDGF binding to
IN, corroborate with the sequence of events during early
stages of HIV-1 replication. IN first encounters vDNA in the
cytoplasm, in which the exchange of subunits in multimers
may be essential for the effective assembly of the fully func-
tional nucleoprotein complex termed the preintegration com-
plex. LEDGF then engages the preassembled IN-vDNA com-
TABLE 1
Binding energy results for docking 1 in the CCD dimer
Conformation Binding Energy Cavity Selected
kcal/mol
1 5.30 Magenta
2 4.34 Magenta
3 3.81 Magenta
4 3.25 Magenta
5 2.69 Magenta
6 2.69 Magenta/orange
7 2.64 Magenta
8 2.09 Magenta/orange
9 1.49 Magenta
10 1.42 Magenta
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plex in the nucleus and tethers PICs to the chromatin
without disturbing the structural arrangements of IN with
its DNA substrates.
This chronology of events would suggest that IN before its
binding to vDNA rather than PICs could be a plausible target
for allosteric inhibitors. Indeed, PICs have a very stable
structure and are likely to be resistant to conformational
challenges with small allosteric compounds. In contrast, un-
liganded IN at earlier stages of viral replication, before syn-
thesis of vDNA by reverse transcriptase is complete, could be
vulnerable to the attack by allosteric inhibitors. This notion
is supported by the published data (De Rijck et al., 2006;
Llano et al., 2006a) indicating that the overexpression of the
enhanced green fluorescent protein-IBD, which lacks nuclear
localization signal and interacts with unliganded IN in the
cytoplasm, effectively inhibits HIV-1 integration. The IBD-
derived short peptides have also been shown to consistently
stabilize IN multimers in vitro and impair HIV-1 integration
in the infected cells (Hayouka et al., 2007; Al-Mawsawi et al.,
2008).
Despite certain mechanistic similarities between the IBD-
and 1-dependent inactivation of IN activities, binding modes
of and oligomerization pathways induced by these ligands
could differ. For example, the IBD establishes extensive con-
tacts with the CCD of one dimer and the N-terminal domain
of another dimer to stabilize a tetramer of IN (McKee et al.,
2008). In contrast, the binding site of 1 is likely to be re-
stricted to a much smaller area. Our results (Figs. 2 and 6)
suggest that 1 binds at the IN dimer interface at an allosteric
pocket, which differs from the IBD binding sites. The result-
ing inhibitor-IN complex may lack sufficient flexibility to
carry out catalytic reactions. Future structural studies of the
inhibitor-protein complex are necessary to gain important
details for how 1 affects the multimeric structure of IN.
Our MS (Fig. 2) and molecular modeling experiments (Fig.
6) have provided initial clues about the amino acids interact-
ing with 1. Unfortunately, the mutagenesis studies did not
allow us to elucidate whether the proposed residues directly
engage the inhibitor because the single amino acid substitu-
tions adversely affected both the inhibitor binding and pro-
tein multimerization (Fig. 7). Nevertheless, mutagenesis ex-
periments have highlighted the architectural importance of
residues within the proposed inhibitor binding site and sug-
gest that a correctly assembled IN multimer is a selective
target for 1. There are the following key advantages for
targeting the proposed allosteric pocket with small-molecule
compounds. The pocket is significantly distanced from pre-
sumed STI binding sites. For example, IN mutations confer-
ring resistance to Raltegravir are localized in the vicinity of
the catalytic DDE motif (Cooper et al., 2008). Therefore,
agents selectively binding at the protein dimer interface are
likely to be active against IN phenotypes resistant to the STI.
Furthermore, the inhibitors targeting the allosteric cavity
(Fig. 6) would not have to compete with IN–IN or IN–LEDGF
interactions. Structural studies indicate extensive monomer-
monomer interfaces within dimeric IN (Chen et al., 2000;
Wang et al., 2001). The LEDGF contacts in IN include two
separate areas in the CCD and the N-terminal domain
(Cherepanov et al., 2005; McKee et al., 2008; Hare et al.,
2009). Therefore, finding small compounds that interfere
with intra- or interprotein-protein interactions could be chal-
lenging. In contrast, 1 is not required to overcome large
energy barriers created by numerous interacting amino ac-
ids. Instead, the inhibitor exploits the preformed dimer in-
terface, which is fully distinct from the LEDGF binding site.
The other two small-molecule inhibitors (3,4-dihydroxy-
phenyltriphenylarsonium bromide and a coumarin-based
compound) of IN have also been shown to interact with the
CCD dimer interface (Molteni et al., 2001; Al-Mawsawi et al.,
2006). However, their mechanisms of inhibition have not
been elucidated. It is possible that these agents also function
by dynamic modulation of IN multimeric structure. Our re-
cently reported subunit-subunit exchange assay (Fig. 4) (Mc-
Kee et al., 2008) provides a means to examine SAR for these
and related compounds.
Our assays enabled us to delineate mechanisms of action
for 1 and authentic CA class inhibitors (see Figs. 2–4 and
supplemental Fig. 2). Unlike 1, 2 failed to interact with the
IN dimer interface and instead impaired IN-DNA complex
formation. The hydroxylated and tetra-acetylated CAs have
been examined previously in the cell culture assays (King
and Robinson, 1998; Pluymers et al., 2000). Robinson and
coworkers (King and Robinson, 1998) isolated a CA resistant
strain containing a mutation in the IN gene corresponding to
the G140S IN variant. However, subsequent studies with
hydroxylated and tetra-acetylated CAs mapped resistant
mutations to the gp120 gene, suggesting that these com-
pounds may target multiple sites in infected cells (Pluymers
et al., 2000).
1 has not been tested in the cell culture assays. However,
the presence of di-O-acetyl groups in this inhibitor is likely to
adversely affect its specificity. For example, these groups are
substrates for cellular acetyltransferases, and the resulting
catechols could deter 1 from its retroviral target. Compara-
tive SAR and molecular modeling studies (Figs. 2, 4, and 6)
suggest that the central linker establishes extensive hydro-
gen bonding network with IN subunits, whereas contribu-
tions of di-O-acetyl groups to the 1-IN complex formation are
relatively limited. Therefore, the tetra-acetate groups, in the-
ory, could be replaced by alternative structures without com-
promising the binding specificity. In fact, continued optimi-
zation of the 1 structure could lead to the identification of
more potent inhibitors with desired specificity in the infected
cells.
Taken together, the mechanism of action and binding site
for the small-molecule inhibitor described herein provides an
attractive venue for targeting IN. Furthermore, our findings
facilitate wider ongoing efforts in the field to develop new
types of clinically useful allosteric inhibitors of IN that could
effectively complement current antiretroviral therapies.
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